Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2025-11-18 Major Shareholding Noti…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a formal notification of a change in major shareholding (flaggningsmeddelande) for Medivir Aktiebolag, where N.G.L. Förvaltning AB has sold its entire stake (5,700,000 shares), dropping below the 5% threshold. This is a standard regulatory disclosure regarding significant share ownership changes.
2025-11-18 Swedish
Medivir offentliggör informationsdokument avseende företrädesemission
Capital/Financing Update Classification · 98% confidence The document is a press release from Medivir AB announcing the publication of an 'informationsdokument' (information document) regarding a rights issue (företrädesemission). It explicitly states that the document is not a prospectus and provides details on the offering, timeline, and advisors. Since the document serves as an announcement regarding the release of a specific regulatory document (the information document) and is not the full prospectus or financial report itself, it falls under the category of a Report Publication Announcement.
2025-11-14 Swedish
Medivir publishes disclosure document regarding rights issue
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the publication of a disclosure document related to a rights issue (a capital raise). It explicitly states that the disclosure document has been registered and is available on the company's website, rather than being the disclosure document itself. Following the 'Menu vs Meal' rule, this is an announcement of a report/document publication, which falls under the Report Publication Announcement (RPA) category.
2025-11-14 English
BULLETIN FROM EXTRAORDINARY GENERAL MEETING in MEDIVIR AB (PUBL)
AGM Information Classification · 100% confidence The document is a bulletin from an Extraordinary General Meeting (EGM) of Medivir AB. It details the resolutions adopted at the meeting, including the election of board members, remuneration, reduction of share capital, and the approval of a rights issue of new common shares. While it contains information about voting results and capital changes, the primary purpose is to report the outcomes of the general meeting. According to the filing definitions, documents detailing resolutions and voting results from general meetings are classified as DVA (Declaration of Voting Results & Voting Rights Announcements).
2025-11-10 English
KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I MEDIVIR AB (PUBL)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'Kommuniké' (communiqué) from an Extraordinary General Meeting (Extra bolagsstämma) of Medivir AB. It details the decisions made by shareholders, including board elections, capital reduction, approval of a rights issue (företrädesemission), and amendments to the articles of association. Since this document reports the official outcomes and resolutions of a shareholder meeting, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2025-11-10 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to September 2025. It contains detailed financial summaries (income statement, cash flow, liquidity), management commentary, and operational updates on clinical trials and business development. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2025
2025-11-06 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.